赛马鲁肽
医学
2型糖尿病
恶心
不利影响
杜拉鲁肽
糖尿病
呕吐
体重
内科学
药效学
口服
内分泌学
利拉鲁肽
药代动力学
作者
Rune Viig Overgaard,Christin L. Hertz,Steen H. Ingwersen,Andrea Navarria,Daniel J. Drucker
标识
DOI:10.1016/j.xcrm.2021.100387
摘要
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events (AEs) are dependent on the route of administration has not been determined. We demonstrate that nearly identical exposure-response pharmacodynamic relationships are determined by plasma semaglutide levels achieved through oral versus injectable administration for changes in HbA1c, body weight, biomarkers of cardiovascular risk, and AEs such as nausea and vomiting. At typical exposure levels for oral semaglutide, the estimated response is 1.58% (oral) versus -1.62% (subcutaneous) for HbA1c and 3.77% (oral) versus 3.48% (subcutaneous) reduction in body weight relative to baseline after 6 months. Increased body weight is the most important variable associated with reduced semaglutide exposure for both formulations. Hence, interindividual variation in GLP-1R responsivity or route of administration are not major determinants of GLP-1RA effectiveness in the clinic.
科研通智能强力驱动
Strongly Powered by AbleSci AI